Edition:
United States

OPKO Health Inc (OPK.O)

OPK.O on Nasdaq

10.97USD
9 Dec 2016
Change (% chg)

$0.16 (+1.48%)
Prev Close
$10.81
Open
$10.90
Day's High
$11.11
Day's Low
$10.84
Volume
2,656,609
Avg. Vol
3,374,819
52-wk High
$11.85
52-wk Low
$7.12

Latest Key Developments (Source: Significant Developments)

Opko Health qtrly diluted income per share $0.02
Monday, 8 Aug 2016 04:05pm EDT 

Opko Health Inc : Opko health reports improved financial and operating results . Qtrly diluted income per share $ 0.02 .Qtrly total revenue $357.1 million versus $42.4 million.  Full Article

Opko Health says Transition Therapeutics will pay co fee of $3 mln if deal is terminated -SEC filing
Thursday, 30 Jun 2016 10:17am EDT 

Opko Health : If agreement is terminated under certain circumstances Transition Therapeutics will be required to pay co termination fee of $3 million Source: (http://1.usa.gov/29cpxUH ) Further company coverage: [OPK.O] (Bengaluru Newsroom: +1 646 223 8780).  Full Article

Opko Health to acquire Transition Therapeutics
Thursday, 30 Jun 2016 02:00am EDT 

Opko Health Inc : Says under terms, Transition Therapeutics security holders to receive approximately 6.4 million shares of Opko common stock . Says transaction is valued at approximately us$60 million, or us$1.55 per share of Transition Therapeutics common stock . Says deal approved by boards of directors of both companies .Opko Health to acquire Transition Therapeutics.  Full Article

OPKO Health says FDA approves new drug application for Rayaldee
Tuesday, 21 Jun 2016 02:00am EDT 

OPKO Health : Fda Approves New Drug Application For Rayaldee® To Treat Secondary Hyperparathyroidism Associated With Vitamin D Insufficiency In Stage 3 . Says u.s. Launch planned for 2h 2016 . Says approval based upon two randomized, double blind, placebo controlled trials and an open label extension study . Vitamin d insufficiency was corrected in more than 80% of patients receiving rayaldee versus less than 7% of subjects receiving placebo .4 chronic kidney disease.  Full Article

Opko Health moves to Nasdaq
Monday, 13 Jun 2016 09:10am EDT 

Opko Health Inc : Opko Health announces move to Nasdaq stock market . Expects its common stock will begin trading on Nasdaq global select market on June 24, 2016 .Shares will continue to trade under ticker symbol "OPK".  Full Article

Opko Health reports Q1 loss per share $0.02
Monday, 9 May 2016 04:13pm EDT 

Opko Health Inc : Qtrly loss per share $0.02 . Q1 earnings per share view $-0.03, revenue view $266.3 million -- Thomson Reuters I/B/E/S .Q1 revenue $291 million versus i/b/e/s view $266.3 million.  Full Article

Opko Health unit and Vifor Fresenius Medical Care enter into development and license deal
Monday, 9 May 2016 08:47am EDT 

Opko Health Inc : Co's unit and Vifor Fresenius Medical Care Pharma entered into development and license deal for development and marketing of Rayaldee . Under terms, eirgen granted to vfmcrp an exclusive license in territory in field to use certain eirgen patents and technology . Eirgen will receive an initial payment of $50 million within ten business days after effective date of agreement . As part of arrangement, cos will share responsibility for conduct of trials specified within agreed-upon development plan . Co's unit eirgen is also eligible to receive up to an additional aggregate amount of $232 million upon achievement of certain milestones . Vfmcrp will be responsible for all other development costs that vfmcrp considers necessary to develop product - sec filing . Eirgen granted to vfmcrp an exclusive option to acquire an exclusive license under certain eirgen patents . In connection with option to buy exclusive licence, vfmcrp would pay eirgen up to additional $555 million upon achievement of milestones .In connection with option to buy exclusive licence, vfmcrp would be obligated to pay double digit royalties on vfmcrp's sales in us.  Full Article

OPKO Health, Inc says Accepts Resubmission of New Drug Application for RAYALDEE®
Wednesday, 27 Apr 2016 12:43pm EDT 

OPKO Health, Inc:Says FDA has accepted OPKO's resubmission on April 22, 2016 of the New Drug Application (NDA) for RAYALDEE((reg))(calcifediol).Says six month review period has been assigned for the resubmitted NDA, and the new Prescription Drug User Fee Act (PDUFA) date will be October 22, 2016.  Full Article

Xenetic Biosciences Inc says Opko Health acquired about 6.3 pct interest in Xenetic
Friday, 12 Feb 2016 09:30am EST 

OPKO health Inc:Has acquired an approximate 6.3% interest in Xenetic Biosciences, Inc.  Full Article

OPKO Health Inc announces global license agreement for Discovery of Novel Antimicrobials
Wednesday, 9 Sep 2015 09:00am EDT 

OPKO Health Inc:Announced a global license agreement with The Scripps Research Institute (TSRI) for the development and commercialization of novel lipoprotein signal peptidase.Has agreed to fund additional work in Dr. Wolan's laboratory at TSRI and to move as rapidly as possible into clinical trials.  Full Article

BRIEF-OPKO Health to begin shipments of Rayaldee capsules to U.S. distributors on Nov. 29

* Will commence shipments of Rayaldee (Calcifediol) extended-release capsules to distributors in U.S. on Tuesday, November 29, 2016 Source text for Eikon: Further company coverage: